ASH: CAR T - Cell Therapy Promising for Relapsed/Refractory iNHL

Phase 2 study reveals high objective response rate for CAR T - cell therapy in patients with follicular lymphoma, marginal zone lymphoma
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Conference News, Source Type: news